Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Privileged structures as leads in medicinal chemistry.

Luca Costantino1, Daniela Barlocco

  • 1University of Modena e Reggio Emilia, Dipartimento di Scienze Farmaceutiche, Via Campi 183, 41100 Modena, Italy. costantino.luca@unimo.it

Current Medicinal Chemistry
|February 7, 2006
PubMed
Summary

Privileged structures, key molecular fragments for drug discovery, can interact with multiple targets. Understanding their structure-target relationships is crucial for efficient new drug development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real world effectiveness of anti-CGRP monoclonal antibodies over three consecutive one-year treatment cycles: An intention-to-treat analysis.

Cephalalgia : an international journal of headache·2025
Same author

Novel Antibacterial Agents 2022.

Pharmaceuticals (Basel, Switzerland)·2024
Same author

The discovery of aryl-2-nitroethyl triamino pyrimidines as anti-Trypanosoma brucei agents.

European journal of medicinal chemistry·2023
Same author

Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth.

eLife·2022
Same author

Selective Inhibitors of Histone Deacetylase 10 (HDAC-10).

Current medicinal chemistry·2021
Same author

Special Issue "Novel Antibacterial Agents".

Pharmaceuticals (Basel, Switzerland)·2021

Area of Science:

  • Medicinal Chemistry
  • Drug Discovery
  • Pharmacology

Background:

  • Privileged structures are molecular fragments capable of interacting with multiple biological targets.
  • Their identification, primarily through empirical observation, accelerates the drug discovery process.
  • These structures can exhibit specificity for a single protein family or promiscuity across unrelated targets.

Purpose of the Study:

  • To review privileged structures not covered in recent literature.
  • To highlight the critical role of structure-target relationships in defining privileged status.
  • To advance the understanding of privileged structures in drug discovery.

Main Methods:

  • Literature review focusing on underrepresented privileged structures.

Related Experiment Videos

  • Analysis of structure-activity relationships for identified molecular fragments.
  • Synthesis of information on structure-target interactions.

    • Main Results:

    • Identification of novel or under-discussed privileged structures.
    • Elucidation of specific structural features responsible for privileged status.
    • Demonstration of diverse target interactions for these fragments.

    Conclusions:

    • Privileged structures are vital for efficient drug discovery.
    • A deep understanding of structure-target relationships is essential for leveraging privileged structures.
    • Further research into under-explored privileged structures can yield new therapeutic leads.